JP2002507209A - カルボン酸類及びその誘導体並びにそれらを含有する医薬組成物 - Google Patents
カルボン酸類及びその誘導体並びにそれらを含有する医薬組成物Info
- Publication number
- JP2002507209A JP2002507209A JP50539899A JP50539899A JP2002507209A JP 2002507209 A JP2002507209 A JP 2002507209A JP 50539899 A JP50539899 A JP 50539899A JP 50539899 A JP50539899 A JP 50539899A JP 2002507209 A JP2002507209 A JP 2002507209A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- hnf
- hydroxy
- dimethyl
- coa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.医療上有効量の式R−COOHの化合物、但し、式中Rは、炭素原子10 −24の飽和または不飽和のアルキル鎖を意味し、該炭素原子の一つまたはそれ 以上がヘテロ原子で置換されていてもよく、所望により該炭素またはヘテロ原子 鎖メンバーの一つまたはそれ以上が環の一部を構成しており、所望により該鎖は ヒドロカルビル基、ヘテロシクリル基、低級アルコキシ、ヒドロキシル置換低級 アルキル、ヒドロキシル、カルボキシル、ハロゲン、フェニルまたは(ヒドロキ シ−、低級アルキル−、低級アルコキシ−、低級アルケニル−または低級アルキ ニル)−置換フェニル、C3−C7シクロアルキルまたは(ヒドロキシ−、低級ア ルキル−、低級アルコキシ−、低級アルケニル−または低級アルキニル)−置換 C3−C7シクロアルキルで置換されており、該化合物は、それぞれの補酵素Aチ オエステル、RCOSCoA、に生体内で転換され得るものである、 または、該化合物の塩、エステルまたはアミドを含んでなる、医薬組成物。 2.Rが、ω−カルボキシル、ω−ヒドロキシルボロン、およびω−ヒドロキ シル鎖からなる群から選ばれるものである、請求項1に記載の組成物。 3.RCOOHが、クロフィブリン酸またはフィブリン酸、またはそれらの塩 、エステル、アミド、または誘導体のいずれかである、請求項1に記載の組成物 。 4.RCOOHが、非ステロイド性坑炎症薬(NSAID)である、請求項1 に記載の組成物。 5.RCOOHが、長鎖脂肪酸である、請求項1に記載の組成物。 6.脂肪酸が、 ステアリン(18:0)酸 オレイン(18:1)酸 リノレイン(18:2)酸 リノレイン(18:3)酸 アイコサペンタエン(20:5)酸 ドコサヘキサン(22:6)酸 から選ばれるものである、請求項5に記載の組成物。 7.有効性化合物が下記化合物、但し、式中Rがω−カルボキシルであり、そ して、RCOOHが、 1、16−ヘキサデカンジオイック酸、 1、18−オクタデカンジオイック酸、 2、2、15、15−テトラメチル−ヘキサンデカン−1、16−ジオイック酸 、 2,2,17,17−テトラメチル−オクタデカン−1、18−ジオイック酸、 3、3、14、14−テトラメチル−ヘキサデカン−1、16−ジオイック酸、 3、3、16、16−テトラメチル−オクタデカン−1、18−ジオイック酸、 4、4、13、13−テトラメチル−ヘキサデカン−1、16−ジオイック酸、 および 4、4、15、15−テトラメチル−オクタデカン−1、18−ジオイック酸、 からなる群から選ばれるものである、請求項1に記載の組成物。 8.Rがω−ヒドロキシボロンであり、そして、RCOOHが、 16−B(OH)2−ヘキサデカン酸、 18−B(OH)2−オクタデカン酸、 16−B(OH)2−2,2−ジメチル−ヘキサデカン酸、 18−B(OH)2−2,2−ジメチル−オクタデカン酸、 16−B(OH)2−3,3−ジメチル−ヘキサデカン酸、 18−B(OH)2−3,3−ジメチル−オクタデカン酸、 16−B(OH)2−4、4−ジメチル−ヘキサデカン酸、 18−B(OH)2−4、4−ジメチル−オクタデカン酸、 からなる群から選ばれるものである、請求項1に記載の組成物。 9.Rがω−ヒドロキシであり、そして、RCOOHが、 16−ヒドロキシ−ヘキサデカン酸、 18−ヒドロキシ−オクタデカン酸、 16−ヒドロキシ−2,2−ジメチル−ヘキサデカン酸、 18−ヒドロキシ−2,2−ジメチル−オクタデカン酸、 16−ヒドロキシ−3、3−ジメチル−ヘキサデカン酸、 18−ヒドロキシ−3、3−ジメチル−オクタデカン酸、 16−ヒドロキシ−4、4−ジメチル−ヘキサデカン酸、 18−ヒドロキシ−4、4−ジメチル−オクタデカン酸、 からなる群から選ばれるものである、請求項1に記載の組成物。 10.異リポ蛋白血症(高コレステロール血症、高トリグリセリド血症、低HD L−コレステロール症)処置用の、請求項1ないし9のいずれかに記載の組成物 。 11.インシュリン抵抗性、グルコース耐性不全症、およびNIDDM処置用の 、請求項1ないし9のいずれかに記載の組成物。 12.本態性高血圧症処置用の、請求項1ないし9のいずれかに記載の組成物。 13.血液凝固能低下用、または血液繊維素溶解増加用の、請求項1ないし9の いずれかに記載の組成物。 14.代謝性症状(症状−X)の処置用、請求項1ないし9のいずれかに記載の 組成物。 15.アテローム性冠状または末梢動脈硬化症の処置用、請求項1ないし9のい ずれかに記載の組成物。 16.リューマチ様関節炎、多発性硬化症、腸性乾癬または炎症の処置用、請求 項1ないし9のいずれかに記載の組成物。 17.胸部癌、結腸癌、または、前立腺癌の処置用、請求項1ないし9のいずれ かに記載の組成物。 18.局所使用用、請求項1ないし9のいずれかに記載の組成物。 19.HNF−4制御転写を阻害する化合物を医療上有効量投与することを含ん で成る、症状−X処置方法。 20.該化合物が、それぞれのCoAチオエステルに転換され得る両親媒性カル ボキシレートである、請求項19に記載の方法。 21.該両親媒性カルボキシレートが、異種生物性両親媒性カルボキシレートで ある、請求項20に記載の方法。 22.該化合物が、二量体−オリゴマー平衡をオリゴマーに有利な方向にシフト させるものである、請求項19に記載の方法。 23.該化合物が、標的遺伝子に対するHNF−4二量体の結合親和性を減少さ せるものである、請求項19または28に記載の方法。 24.長鎖脂肪酸を医療上有効量投与することを含むものである、請求項19に記 載の方法。 25.該両親媒性カルボキシレートが、不飽和脂肪酸である、請求項20に記載の 方法。 26.該両親媒性カルボキシレートが、ポリ不飽和脂肪酸である、請求項20に記 載の方法。 27.該両親媒性カルボキシレートが、炭素原子約12−24の脂肪酸である、 請求項20に記載の方法。 28.両親媒性カルボキシレートを医療上有効量投与することを含んでなる、H NF−4α転写活性の調節方法。 29.該調節が、HNF−4活性の阻害である、請求項28に記載の方法。 30.該調節が、HNF−4活性の活性化である、請求項28に記載の方法。 31.該両親媒性カルボキシレートが、C18:3脂肪酸である、請求項20また は28に記載の方法。 32.該両親媒性カルボキシレートが、C20:5脂肪酸である、請求項20また は28に記載の方法。 33.該両親媒性カルボキシレートが、それぞれのCoAチオエステルに転換さ れ得る脂肪酸である、請求項20または28に記載の方法。 34.アテローム性冠状または末梢動脈硬化症処置のための、請求項28に記載の 方法。 35.リューマチ様関節炎、多発性硬化症、腸性乾癬または炎症処置のための、 請求項28に記載の方法。 36.胸部癌、結腸癌、または、前立腺癌の処置処置のための、請求項28に記載 の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL121165 | 1997-06-26 | ||
IL12116597A IL121165A0 (en) | 1997-06-26 | 1997-06-26 | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
PCT/IB1998/000968 WO1999000116A2 (en) | 1997-06-26 | 1998-06-23 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002507209A true JP2002507209A (ja) | 2002-03-05 |
JP2002507209A5 JP2002507209A5 (ja) | 2005-12-22 |
Family
ID=11070308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50539899A Ceased JP2002507209A (ja) | 1997-06-26 | 1998-06-23 | カルボン酸類及びその誘導体並びにそれらを含有する医薬組成物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US6303653B1 (ja) |
EP (1) | EP1001755B1 (ja) |
JP (1) | JP2002507209A (ja) |
CN (2) | CN101129349A (ja) |
AT (1) | ATE508739T1 (ja) |
AU (1) | AU7783998A (ja) |
CA (1) | CA2294232A1 (ja) |
IL (2) | IL121165A0 (ja) |
RU (1) | RU2239427C2 (ja) |
WO (1) | WO1999000116A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010519290A (ja) * | 2007-02-26 | 2010-06-03 | シンドロメクス リミテッド | 心血管系障害の治療のための併用療法、組成物及び方法 |
JP2012515171A (ja) * | 2009-01-14 | 2012-07-05 | ヴァナス オンコロジー | 組成物および使用の方法 |
JP2012522790A (ja) * | 2009-03-31 | 2012-09-27 | ウィッテン,マシュー,アール. | 組成物および使用の方法 |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020037876A1 (en) * | 1998-06-25 | 2002-03-28 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
WO2000059855A1 (en) | 1999-04-01 | 2000-10-12 | Esperion Therapeutics, Inc. | Ether compounds, compositions, and uses thereof |
JP2004505041A (ja) * | 2000-08-02 | 2004-02-19 | ファーマニュートリエンツ | シンドロームxの予防及び治療のための方法及び組成物 |
JPWO2002024227A1 (ja) * | 2000-09-20 | 2004-01-29 | 協和醗酵工業株式会社 | 腫瘍細胞増殖抑制剤 |
WO2002030882A2 (en) | 2000-10-11 | 2002-04-18 | Esperion Therapeutics, Inc. | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
US7304093B2 (en) | 2000-10-11 | 2007-12-04 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
CN1283610C (zh) | 2000-10-11 | 2006-11-08 | 埃斯佩里安医疗公司 | 用于控制胆固醇以及相关用途的酮化合物以及组合物 |
BR0114619A (pt) | 2000-10-11 | 2005-12-13 | Esperion Therapeutics Inc | Composto, composição farmacêutica, métodos para tratar ou prevenir uma doença cardiovascular, uma dislipidemia, uma dislipoproteinemia, um distúrbio do metabolismo da glicose, trombótico e associado com o receptor ativado do proliferador de peroxissoma, a doença de alzheimer, a sìndrome x ou sìndrome metabólica, a septicemia, a obesidade, pancreatite, a hipertensão, doença renal, câncer, a inflamação e a impotência, em um paciente e para reduzir o teor de gordura da carne em animal de criação e de colesterol de ovos de aves domésticas |
EP1351916A2 (en) | 2000-10-11 | 2003-10-15 | Esperion Therapeutics Inc. | Ether compounds and compositions for cholesterol management and related uses |
NO20006008L (no) * | 2000-11-28 | 2002-05-29 | Thia Medica As | Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer |
WO2003105860A1 (en) * | 2002-06-14 | 2003-12-24 | Novo Nordisk A/S | Pharmaceutical use of boronic acids and esters thereof |
SI2404890T1 (sl) | 2003-01-23 | 2017-12-29 | Esperion Therapeutics Inc. | Hidroksilne spojine in sestavki za uravnavanje holesterola in sorodne uporabe |
AU2003304703A1 (en) | 2003-12-24 | 2005-08-03 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
KR20070015114A (ko) * | 2003-12-30 | 2007-02-01 | 신드로멕스 리미티드 | 3,3,14,14 테트라메틸 헥사데칸 1,16 이산의 투여 방법 |
KR101431279B1 (ko) | 2005-07-29 | 2014-08-20 | 리스버로직스 코퍼레이션 | 복합 질환의 예방 및 치료용 약학적 조성물 및 삽입가능한의료 장치에 의한 이의 전달 |
WO2007137864A1 (en) * | 2006-06-01 | 2007-12-06 | Eucro European Contract Research Gmbh & Co. Kg | Use of inhibitors of pp2c for treating or preventing arteriosclerosis |
WO2008018877A1 (en) | 2006-08-11 | 2008-02-14 | Ssv Therapeutics, Inc. | Carnitine conjugates as dual prodrugs, methods of production and uses thereof |
ES2454966T3 (es) | 2007-02-01 | 2014-04-14 | Resverlogix Corp. | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
EP2431043A1 (en) | 2007-05-23 | 2012-03-21 | Amcol International Corporation | Cholesterol-interacting layered phyllosilicates for suppressing gastrointestinal cholesterol absorption |
DE102007051339A1 (de) * | 2007-10-26 | 2009-04-30 | Müller-Enoch, Dieter, Prof. Dr. | Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptablen Salze zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung und zur Vorbeugung von Dyslipidämien |
EP2085082A1 (en) * | 2008-01-29 | 2009-08-05 | Nutromnia S.R.L. | Treatment of cognitive decline |
RU2520098C2 (ru) | 2008-06-26 | 2014-06-20 | Ресверлоджикс Корп. | Способы получения производных хиназолинона |
WO2010079431A2 (en) | 2009-01-08 | 2010-07-15 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
NZ595747A (en) | 2009-03-18 | 2015-06-26 | Resverlogix Corp | Novel quinazolinones and related compounds for use as anti-inflammatory agents |
KR20190091564A (ko) | 2009-04-22 | 2019-08-06 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
MY163512A (en) | 2009-09-03 | 2017-09-15 | Pfizer Vaccines Llc | Pcsk9 vaccine |
US20140004142A1 (en) | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
PT2773354T (pt) | 2011-11-01 | 2019-07-17 | Resverlogix Corp | Formulações orais de libertação imediata para quinazolinonas substituídas |
US10479752B2 (en) * | 2011-12-08 | 2019-11-19 | Syndromex Ltd. | Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
WO2014096965A2 (en) | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
CN114099496A (zh) | 2015-03-13 | 2022-03-01 | 艾斯柏伦治疗公司 | 含etc1002和依泽替米贝的组合及治疗方法 |
JO3789B1 (ar) | 2015-03-13 | 2021-01-31 | Resverlogix Corp | التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة |
MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
US20180092874A1 (en) * | 2016-10-03 | 2018-04-05 | Lincoln Memorial University | Identification and use of very long chain dicarboxylic acids for disease diagnosis, chemoprevention, and treatment |
EP3986859A1 (en) | 2019-06-21 | 2022-04-27 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL64542A0 (en) * | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
DE3423166A1 (de) | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
GB8819110D0 (en) * | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
DE4224670A1 (de) | 1992-07-25 | 1994-01-27 | Boehringer Mannheim Gmbh | Verwendung von â,w-Dicarbonsäuren als Fibrinogensenker |
ATE183391T1 (de) * | 1993-12-31 | 1999-09-15 | Univ Limburg | Verwendung von zusammensetzungen essentieller fettsäuren |
IL119971A (en) | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
ID22744A (id) * | 1997-02-21 | 1999-12-09 | Abbott Lab Cs | Metoda dan komposisi untuk mengurangi pengaruh dari nekrotisasi enterkolitis |
-
1997
- 1997-06-26 IL IL12116597A patent/IL121165A0/xx unknown
-
1998
- 1998-06-23 CA CA002294232A patent/CA2294232A1/en not_active Abandoned
- 1998-06-23 WO PCT/IB1998/000968 patent/WO1999000116A2/en active Application Filing
- 1998-06-23 JP JP50539899A patent/JP2002507209A/ja not_active Ceased
- 1998-06-23 AU AU77839/98A patent/AU7783998A/en not_active Abandoned
- 1998-06-23 RU RU2000101334/15A patent/RU2239427C2/ru not_active IP Right Cessation
- 1998-06-23 CN CNA2007101516440A patent/CN101129349A/zh active Pending
- 1998-06-23 EP EP98925875A patent/EP1001755B1/en not_active Expired - Lifetime
- 1998-06-23 AT AT98925875T patent/ATE508739T1/de not_active IP Right Cessation
- 1998-06-23 CN CN98806550A patent/CN1261274A/zh active Pending
- 1998-06-25 US US09/104,880 patent/US6303653B1/en not_active Expired - Fee Related
-
1999
- 1999-12-15 IL IL133540A patent/IL133540A/en not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010519290A (ja) * | 2007-02-26 | 2010-06-03 | シンドロメクス リミテッド | 心血管系障害の治療のための併用療法、組成物及び方法 |
JP2012515171A (ja) * | 2009-01-14 | 2012-07-05 | ヴァナス オンコロジー | 組成物および使用の方法 |
JP2012522790A (ja) * | 2009-03-31 | 2012-09-27 | ウィッテン,マシュー,アール. | 組成物および使用の方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1261274A (zh) | 2000-07-26 |
IL121165A0 (en) | 1997-11-20 |
US6303653B1 (en) | 2001-10-16 |
EP1001755B1 (en) | 2011-05-11 |
ATE508739T1 (de) | 2011-05-15 |
IL133540A (en) | 2009-09-22 |
EP1001755A2 (en) | 2000-05-24 |
AU7783998A (en) | 1999-01-19 |
WO1999000116A2 (en) | 1999-01-07 |
CA2294232A1 (en) | 1999-01-07 |
WO1999000116A3 (en) | 1999-08-12 |
CN101129349A (zh) | 2008-02-27 |
RU2239427C2 (ru) | 2004-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002507209A (ja) | カルボン酸類及びその誘導体並びにそれらを含有する医薬組成物 | |
Urade et al. | Prostaglandins and sleep–wake regulation | |
Baxter et al. | Selective modulation of thyroid hormone receptor action | |
US5874459A (en) | Anandamide amidase inhibitors as analgesic agents | |
US5981586A (en) | Methods for treating proliferative and inflammatory skin diseases | |
US20100120742A1 (en) | Rexinoid compound having alkoxy group | |
US20110136906A1 (en) | Use of hydroxyoleic acid and related compounds in the manufacture of drugs | |
JP2943089B2 (ja) | イソプレノイドホスホリパーゼ▲a2▼阻害剤およびそれを包含する製剤 | |
EP2745837B1 (en) | Glomerulonephritis Treatment | |
EP1778210A2 (en) | Lipid-amino acid conjugates and methods of use | |
KR20150081433A (ko) | 이베르멕틴 및 이의 유도체의 용도 | |
JP2020526505A (ja) | 脂肪酸誘導体およびこれらの使用 | |
EP1176134A1 (en) | Ligands of nuclear receptors ppar's | |
EP1142870A1 (en) | Novel ligands of nuclear receptor | |
US20020037876A1 (en) | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | |
US20230039244A1 (en) | 2-beta-naphthyl-acetic acid analogs as akr1c3 inhibitors and methods of using same | |
JP2003504644A (ja) | Scapアンタゴニストである治療剤のスクリーニング | |
US8410085B2 (en) | Phospholipid compositions and uses thereof | |
JP2001521539A (ja) | 炎症及び疼痛メディエーターのNf−κB依存性生成阻害剤としてのイブプロフェンチオエステル(炎症及び疼痛メディエーターのNf−κB依存性生成阻害剤としてのアリールプロピオン酸、アリール酢酸及びサリチル酸塩のCoAチオエステル) | |
JPWO2004093910A1 (ja) | PPARδアゴニストによる脳神経変性疾患治療剤 | |
US4939134A (en) | 26-aminocholesterol and derivatives and analogs thereof in the regulation of cholesterol accumulation in body tissue | |
US6673785B1 (en) | Use of hepoxilins or hepoxilin analogs as antidiabetics, antiinflammatory agents | |
Makhlouf et al. | Increased prostacyclin and PGE2 stimulated cAMP production by macrophages from endotoxin-tolerant rats | |
MXPA99012051A (en) | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | |
Cheng et al. | Leukotriene receptors in the airways |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040824 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050616 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050616 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090210 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090601 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090707 |